Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma
A phase 1b/2, open-label, multinational, interventional trial to evaluate the safety,
tolerability, PK, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of
epcoritamab in combination with other standard of care (SOC) agents in subjects with B-NH...
Age: 18 years - 66+
Gender: All
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
A phase 1b/2, open-label, multinational, interventional trial to evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics/biomarkers, immunogenicity, and
preliminary efficacy of epcoritamab in combination with other standard of care (SOC) agents
...
Age: 18 years - 66+
Gender: All
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study will evaluate the efficacy and safety of glofitamab in combination with
gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituximab in combination with
gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.
Age: 18 years - 66+
Gender: All
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the
efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB),
glofitamab, administered by intravenous (IV) infusion as a single agent and in ...
Age: 18 years - 66+
Gender: All
In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
Our recent trials combining local radiotherapy with intratumoral administration of TLR
agonists - referred to as 'in situ vaccination' - for patients with low-grade lymphoma
demonstrated safety, induction of anti-tumor CD8 T cell responses and partial and complete
...
Age: 18 years - 66+
Gender: All